The Net Margin of CRISPR Therapeutics AG (CRSP) is
-16569.77%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-16569.77%
|
| 2024-12-31 |
-981.54%
|
| 2023-12-31 |
-41.38%
|
| 2022-12-31 |
-54183.33%
|
| 2021-12-31 |
41.28%
|
| 2020-12-31 |
-49842.86%
|
| 2019-12-31 |
23.10%
|
| 2018-12-31 |
-5322.58%
|
| 2017-12-31 |
-166.83%
|
| 2016-12-31 |
-446.15%
|
| Ticker |
Name |
Value |
|
ADCT
|
Adc Therapeutics Ltd
|
-175.31%
|
|
MRTX
|
Mirati Therapeutics Inc
|
-5955.55%
|
|
OBSV
|
Obseva SA
|
-290.25%
|
|
RLAY
|
Relay Therapeutics, Inc.
|
-1800.58%
|
|
RVMD
|
Revolution Medicines, Inc.
|
-3768.28%
|
|
TPTX
|
Turning Point Therapeutics Inc
|
-767.30%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
22.69%
|
|
IDIA.SW
|
Idorsia Ltd
|
-50.64%
|
|
VIE
|
Viela Bio Inc
|
-1293.07%
|
|
XLRN
|
Acceleron Pharma Inc
|
-179.45%
|
|
BPMC
|
Blueprint Medicines Corp
|
-13.19%
|
|
ACIU
|
AC Immune AG
|
-1971.65%
|
|
FGEN
|
FibroGen Inc
|
-160.63%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
-40.41%
|
|
RLF.SW
|
Relief Therapeutics Holding SA
|
-203.39%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
-1141542.60%
|
|
ASND
|
Ascendis Pharma A/S
|
-31.67%
|
|
GNRO.PA
|
Geneuro SA
|
-111.59%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
-1170863.70%
|
|
CCXI
|
Churchill Capital Corp XI
|
-408.87%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
-134.73%
|
|
TGTX
|
TG Therapeutics, Inc.
|
72.56%
|
|
UTHR
|
United Therapeutics Corporation
|
41.94%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
2.23%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
-148.38%
|
|
LEGN
|
Legend Biotech Corporation
|
-28.85%
|
|
ALXO
|
ALX Oncology Holdings Inc
|
-3876.27%
|
|
BHVN
|
Biohaven Ltd.
|
-1205.09%
|
|
BSLN.SW
|
Basilea Pharmaceutica AG Allschwil
|
17.32%
|
|
FATE
|
Fate Therapeutics Inc
|
-2051.08%
|
|
MOLN.SW
|
Molecular Partners AG
|
-1087.38%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
-609.85%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
-32.45%
|